Anti-Mouse CD96 – Purified in vivo GOLD™ Functional Grade

Anti-Mouse CD96 – Purified in vivo GOLD™ Functional Grade

Product No.: C781

- -
- -
Clone
3.3
Target
CD96
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
Tactile (T cell-activated increased late expression)
Isotype
Rat IgG1 κ
Applications
B
,
FC
,
in vivo

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Mouse
Host Species
Rat
Recommended Isotype Controls
Recommended Dilution Buffer
Immunogen
Not available or unknown
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
< 1.0 EU/mg as determined by the LAL method
Purity
≥95% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for anti-mouse CD96 antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Additional Applications Reported In Literature ?
B
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Clone 3.3 recognizes an epitope on mouse CD96.
Background
CD96 is a single pass type I transmembrane glycoprotein in the immunoglobulin superfamily that is heavily N-glycosylated1. Murine (m) CD96 is present at the surface of most lymphocytes, including NK, CD4+ T, CD8+ T, NKT, and γδ T cells, but not B lymphocytes, neutrophils, macrophages, or dendritic cells2. mCD96 interacts with mCD155 and nectin-1 (CD111)1. A V-like domain mediates binding of mCD96 to mCD155 via interaction between amino acids of the FG loop of one binding partner with residues in the C’C’’-loop of the other. CD96 is a member of an interaction network that includes adhesion, activation, and inhibition activities.

CD96 contains three Ig-like domains that are separated from the transmembrane domain by a long proline, serine, and threonine rich stalk that undergoes extensive O-linked glycomodification1. The stalk may play a role in orientation or presentation of the Ig-like domains. mAb 3.3 binds to the first Ig domain and competes with CD155 for binding3.

Human CD96 has a mild boosting effect on 2B4- and NKp30-mediated killing, but a direct role in the activation of NK cell-mediated cytotoxicity in vitro has not been observed 1. In contrast, mCD96 suppresses NK cells in vivo2. Blocking studies show that mCD96 competes with CD226 for CD155 binding and limits NK cell function by direct inhibition2. Additionally, blocking mCD96 in vivo with mAb 3.3 protects against metastasis in three different tumor models. The antimetastatic effect of mAb 3.3 is independent of antibody-dependent cell-mediated cytotoxicity and activating Fc receptors3,4 and is enhanced by anti-PD-1 and anti-CTLA-4 mAbs4. Suppression of metastasis by mAb 3.3 is dependent on NK cells, CD226 (DNAM-1), and IFN-γ4. Additionally, mAb 3.3 loses its antimetastatic function in CD155- and IL-12p35-deficient mice3.
Antigen Distribution
Mouse CD96 is mainly expressed by cells of hematopoietic origin, particularly T cells and NK cells.
Ligand/Receptor
CD155, nectin 1
NCBI Gene Bank ID
Research Area
Immunology
.
Inhibitory Molecules

Leinco Antibody Advisor

Powered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments.

Clone 3.3 is a monoclonal antibody used for in vivo blocking of CD96 (also known as TACTILE), a key molecule involved in immune regulation in mice.

In mouse studies, Clone 3.3 is principally used to:

  • Block CD96 function in vivo, enabling investigation of its role in immune cell adhesion, cytotoxicity, and cancer immunotherapy.
  • Suppress primary tumor growth as demonstrated in experimental mouse tumor models.

Key applications in vivo:

  • Administered to mice to inhibit CD96, particularly on NK cells and T cells, to assess effects on immune response and tumor progression.
  • Utilized in tumor metastasis studies and mechanistic cancer immunotherapy models, where blocking CD96 can alter immune cell interactions with target cells.
  • Supplied at ultra-high purity and low endotoxin levels to ensure compatibility in mouse models, minimizing immune reactions unrelated to the experimental hypothesis.

Controls and preparation:

  • Experiments using Clone 3.3 typically include isotype controls such as rat IgG1 to confirm specificity of immune response.
  • Antibody is dissolved in specialized buffers (pH 7.0), rigorously tested for absence of contaminants and murine pathogens, ensuring safety and reproducibility in vivo.

If you are referencing "clone 3.3" in the context of mouse genetics or stem cell cloning rather than monoclonal antibodies, note that the term in research typically denotes a specific monoclonal antibody clone rather than a genetically cloned mouse line. For mouse stem cell or genetic clone models, the procedures and applications differ significantly.

The correct storage temperature for sterile packaged CloneDetect reagents and similar products is -20°C (-4°F) or lower. According to the CloneDetect Detection Reagent Protocol, semi-solid media products and supplements used in sterile cloning workflows should be kept at this temperature to maintain stability for up to 12 months from shipment.

If your query refers to a different “clone 3.3” product, you should reference the manufacturer’s documentation for precise storage guidance. For most sterile packaged biological reagents used in cloning or cell culture, storage at -20°C for long-term stability is standard.

For general sterile packaged items (such as sterile medical supplies), the standard recommended storage is at controlled room temperature between 18°C and 23°C, with relative humidity between 30% and 60%, and always protecting the integrity of the packaging. However, these guidelines do not usually apply to specialized biological reagents.

  • For CloneDetect and related sterile packaged supplements: store at -20°C (-4°F) or lower.
  • For general sterile medical devices or supplies: store at 18°C to 23°C, unless otherwise specified on the packaging or by the manufacturer.

Always verify with the product’s package insert or manufacturer documentation for any product-specific storage instructions.

The specific antibody referred to as "3.3" in your query is ambiguous, as “3.3” on its own is not a standard designation for a commonly known antibody or protein in the literature. The context (e.g., target protein, disease area, or experimental use) is essential to identify associated or co-used antibodies. For clarity, I will address general approaches and commonly paired antibodies or proteins, as described in research literature, especially when working with antibody-based experiments or multimodal assays.

Commonly Used Antibodies and Proteins in Research:

  • Immunoglobulin Isotypes: Different antibody subclasses, such as IgG1, IgG2, IgG3, and IgG4, are often used with other antibodies (e.g., IgA, IgM, etc.) for isotype controls, multiplexing, or subclass-specific effects in immunological research.
  • Secondary Antibodies: These detect primary antibodies like "3.3" (if monoclonal or polyclonal) and are typically anti-mouse IgG, anti-rabbit IgG, etc., conjugated to enzymes or fluorophores for detection in assays such as Western blot, ELISA, and immunofluorescence.
  • Protein Markers and Controls:
    • Housekeeping proteins (e.g., GAPDH, ?-actin) are frequently probed alongside target antibodies to normalize protein loading in quantitative experiments.
    • Tag antibodies (e.g., anti-HA, anti-Myc, anti-His) are used when the protein of interest is expressed using a tagged construct.
  • Complementary or Functional Partners: Multicolor flow cytometry or co-immunoprecipitation often involves using multiple antibodies that recognize ?-chain partners, cell-type markers (e.g., CD3, CD8, CD45, CD19), or interaction partners for the protein targeted by "3.3."
  • Fusion or Multifunctional Proteins: In the case of engineered or multiplexed reagents (e.g., bispecific/trifunctional antibodies), antibodies are combined with cytokines (such as IL-15, IL-21), or engineered for cross-isotype or cross-subtype functions to enhance or diversify effector mechanisms.

If "3.3" refers to a Multispecific/Trifunctional Antibody:

  • Trifunctional or bispecific antibodies are often studied together with other antibody formats (such as scFv, VHH, IgG) and cytokines, or in comparison to monospecific antibodies for functional analysis.
  • Such studies may include paired detection antibodies, isotype controls, or competitors targeting adjacent epitopes.

Key Points:

  • Common antibodies or proteins co-used depend on the experimental context (immunodetection, immunotherapy, multiplexing).
  • If you have a specific target or system (e.g., “3.3” is anti-CD3, anti-?3 integrin, or a different target), established literature often pairs it with other lineage, activation, or functional markers.
  • For antibody drug conjugates, different mAbs, linkers, and small molecules (e.g., trastuzumab-T-DM1) are studied together to compare aggregation propensity and efficacy.

Please provide the full identity or target of "3.3" for more precise information on commonly used antibodies or proteins paired with it in the literature.

Based on the provided search results, I cannot find specific information about "clone 3.3 citations" in scientific literature. The search results contain information about code clone evolution research and recurrent neural networks for clone detection, but do not reference any specific citation system or findings related to "clone 3.3."

Code Clone Evolution Research

The search results do reveal key findings from systematic literature reviews on code clone evolution and detection:

Performance of Clone Detection Techniques: Recent research has shown significant improvements in detecting challenging clone types. Studies using Recurrent Neural Networks (RNNs) have demonstrated enhanced performance in identifying Type-III and Type-IV clones, which are known for their inherent identification complexity. The DFS technique by Ullah et al. achieved exceptional performance with precision, recall, and F1-score values of 99.4%, 99.5%, and 99.4% respectively on the OJClone dataset.

Evolution of Detection Methods: There has been notable improvement in clone detection performance over time, with relatively lower F-Score values in 2017 and 2018 attributed to the early stage of development for deep learning techniques in this domain. More recent approaches have shown substantially better results across multiple benchmarks.

Research Focus Areas: The systematic literature review identified 47 research works in code clone evolution, covering topics such as automatic identification of important clones for refactoring, evolutionary coupling of cloned code, bug propagation through code cloning, and inconsistent changes in code clones.

If you are looking for information about a specific citation format, numbering system, or particular research findings labeled as "clone 3.3," please provide additional context or clarify what specific aspect of clone research you're interested in exploring.

References & Citations

1. Georgiev H, Ravens I, Papadogianni G, et al. Front Immunol. 9:1072. 2018.
2. Chan CJ, Martinet L, Gilfillan S, et al. Nat Immunol. 15(5):431-438. 2014.
3. Roman Aguilera A, Lutzky VP, Mittal D, et al. Oncoimmunology. 7(5):e1424677. 2018.
4. Blake SJ, Stannard K, Liu J, et al. Cancer Discov. 6(4):446-459. 2016.
B
Flow Cytometry
in vivo Protocol

Certificate of Analysis

Formats Available

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.